Minerva

Patient reported outcomes in rheumatology trials and other stories . . .

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2993 (Published 01 June 2016) Cite this as: BMJ 2016;353:i2993

Rheumatology trials and PROMs

Between 1983 and 1988 a series of papers showed that rheumatologists varied considerably in the way they use clinical measures to make judgments about the efficiency of treatment. This led to the formation of OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials), which first met in 1992. A systematic review examines how patient reported outcomes measures (PROMs) have been reported in rheumatology trials since 2007 (J Rheumatol doi:10.3899/jrheum.151177). There has been almost no change. Outcomes identified as important by OMERACT—such as fatigue, sleep disturbance, loss of productivity, and coping—are still rarely reported.

Vitamin B12 associated with brain volume

Humans have a complicated system for extracting vitamin B12 from foods and converting some of it into holotranscobalamin to make it available to the …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe